Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;165(2):492-495.e2.
doi: 10.1053/j.gastro.2023.03.230. Epub 2023 Apr 7.

Low-Dose Interleukin 2 for the Treatment of Moderate to Severe Ulcerative Colitis

Jessica R Allegretti  1 , Vanessa Mitsialis  2 , James B Canavan  3 ; Low-Dose IL2 UC Study Group; Scott B Snapper  4
Collaborators, Affiliations

Low-Dose Interleukin 2 for the Treatment of Moderate to Severe Ulcerative Colitis

Jessica R Allegretti et al. Gastroenterology. 2023 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures:

JRA declares the following interests: Scientific Advisory Board participation for Iterative Scopes and Finch Therapeutics. Consulting for Pandion, Merck Servatus, Janssen, Abbvie, Pfizer, Bristol Myer Squibb (BMS), Summit Therapeutics, Seres Therapeutics, Ferring. Grant support from Merck, Janssen and Pfizer.

SBS declares the following interests: Scientific advisory board participation for Pfizer, Pandion, Celgene, Lilly, Takeda, Cosmo Pharmaceuticals, Merck, Sonoma Biotherapeutics, and EcoR1. Grant support from Pfizer, Amgen Takeda, and Novartis. Consulting for Amgen, Kyverna, BMS, Merck, Third Rock, 89bio, GentiBio and Apple Tree Life Sciences.

JK declares Scientific Advisory Board participation for Cugene, Therakos (Mallinckrodt). Consulting for Equillium, GentiBio, Cue Biopharma, Biolojic Design Research Support from Amgen, Clinigen, BMS, Miltenyi Biotec, Regeneron, Equillium. Legal: Abbvie.

AA has participated in advisory boards for Mentein AI, and Iterative Scopes.

FF declares Consulting Fees from BMS, Braintree Labs, GI Reviewers, GSK, IBD Educational Group, Innovation Pharmaceuticals, Iterative Scopes, Janssen, Pfizer, Sebela. FF has served on the data safety monitoring board for Adiso Pharmaceuticals and Lilly.

HH declares the following interests: Scientific advisory Board participation for AMAG, BMS, Fresenius Kabi, Janssen, Merck, Pfizer, Seres. Consultant for, Alivio, ExeGI Finch, Gilead, Lycera, Otsuka, PureTech Research support from Artizan Biosciences, NovoNordisk, Allakos, Artizan.

All other authors report no relevant disclosures

Figures

Figure 1.
Figure 1.. Complete Mayo Scores, Treg expansion and activation in study patients and mucosal Treg responses pre- and post LD IL-2 induction.
Complete Mayo Scores of all recruited patients at baseline and at Week 8 of LD IL-2 treatment, for those patients who completed the induction (A). Peripheral Treg (pTreg) expansion during the duration of LD IL-2 induction for all recruited patients across all doses (B). pTreg expansion in LD IL-2 responders versus non-responders across all doses, among patients who completed the 8-week induction period (C). Phospho-STAT5 (pSTAT5) expression in pTregs and peripheral Tcons (pTCons) in responders versus non-responders across all doses, among patients who completed the 8-week induction period (D). Mucosal Treg (mTreg) proportions at pre-treatment sigmoidoscopy (Scope 1) and Week 8 sigmoidoscopy (Scope 2) in LD IL-2 responders versus non-responders (E). mTreg proportions at Scope 1 and Scope 2 across all patients who completed the 8-week induction period, across all doses (F). The proportion of mTregs out of CD4+ lymphocytes at Scope 1 and Scope 2 was averaged across biopsied colonic regions for each patient-timepoint. All p values were adjusted using the Benjamini-Hochberg correction for multiple comparisons. Box and whisker plots show the median with lower and upper hinges corresponding to the first and third quartiles (25th and 75th percentiles); and length of whiskers corresponds to 1.5*(interquartile range).
See this image and copyright information in PMC

References

    1. Chang JT. Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med 2020;383:2652–2664. - PubMed
    1. Laukova M, Glatman Zaretsky A. Regulatory T cells as a therapeutic approach for inflammatory bowel disease. Eur J Immunol 2023;53:e2250007. - PMC - PubMed
    1. Humrich JY, Morbach H, Undeutsch R, et al. Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus. Proc Natl Acad Sci U S A 2010;107:204–9. - PMC - PubMed
    1. Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010;207:1871–8. - PMC - PubMed
    1. Hulme MA, Wasserfall CH, Atkinson MA, et al. Central role for interleukin-2 in type 1 diabetes. Diabetes 2012;61:14–22. - PMC - PubMed

Publication types

MeSH terms